 MORRISVILLE, N.C., May 03, 2021 GLOBE NEWSWIRE -- Syneos Health, Inc. Nasdaq: SYNH the Company or Syneos Health, the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation the Selling Stockholders of an aggregate of 7,000,000 shares of the Companys common stock the Offering. The Selling Stockholders have also granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the Selling Stockholders in the Offering. The Offering is expected to close on May 6, 2021, subject to customary closing conditions. 